{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-022333","form_type":"8-K","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.588678+00:00","generated_at":"2026-06-24T00:54:29.426517+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bioventus Q2 net sales up 27.8% to $140.3M; net loss improves to $8.0M; updates FY22 guidance","bullets":["Net sales of $140.3M (+27.8% YoY); organic growth of 8.1%. Surgical Solutions vertical up 77.2%.","GAAP net loss of ($8.0M) vs ($10.8M) in Q2 2021; diluted loss per share ($0.11) vs ($0.10).","Adjusted EBITDA of $22.9M vs $19.9M YoY; Non-GAAP EPS $0.10 vs $0.11.","FY22 guidance narrowed: net sales $547.5-562.5M (mid-point unchanged); adjusted EBITDA $94-104M.","Discontinued MOTYS development; completed CartiHeal acquisition on July 12, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-022333","json":"https://secwatch.observer/filing/0001628280-22-022333.json","markdown":"https://secwatch.observer/filing/0001628280-22-022333.md","text":"https://secwatch.observer/filing/0001628280-22-022333.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000162828022022333/0001628280-22-022333-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000162828022022333/bvs-20220811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:54:29.426517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}